

Product Description

Pioneering GTPase and Oncogene Product Development since 2010


GPCPD1 RABBIT PAB

Cat.#: S219171 Product Name: Anti-GPCPD1 Rabbit Polyclonal Antibody Synonyms: EDI3; GDE5; GDPD6; PREI4 **UNIPROT ID:** Q9NPB8 (Gene Accession - BC027588) Background: May be involved in the negative regulation of skeletal muscle differentiation, independently of its glycerophosphocholine phosphodiesterase activity. Immunogen: Fusion protein of human GPCPD1 Applications: ELISA, WB, IHC Recommended Dilutions: IHC: 50-100;WB: 500-2000;ELISA: 5000-10000 Host Species: Rabbit Clonality: Rabbit Polyclonal Isotype: Immunogen-specific rabbit IgG Purification: Antigen affinity purification Species Reactivity: Human, Mouse, Rat Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol Research Areas: Cell Biology Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing




Product Description


Pioneering GTPase and Oncogene Product Development since 2010




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219171(GPCPD1 Antibody) at a dilution of 1/55(Cytoplasm).



The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using 219171(Anti-GPCPD1 Antibody) at a dilution of 1/55.




In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 219171(Anti-GPCPD1 Antibody) at dilution 1/55.



In comparision with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with fusion protein and then with D225967(Anti-GPCPDI Antibody) at dilution 1/55.





Gel: 8%SDS-PAGE, Lysate: 40 µg; Lane: A549 cell lysate; Primary antibody: 219171(GPCPD1 Antibody) at dilution 1/800; Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution; Exposure time: 50 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010